Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in New Jersey
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in New Jersey
| Provider | Medicare | Services |
|---|---|---|
| Cliffside Labs L.L.C. | $42.78 | 136 |
| Laboratory Corporation Of America... | $42.78 | 121 |
| Quest Diagnostics Incorporated | $41.51 | 66 |
New Jersey Pricing in Context
In New Jersey, CPT code 81332 (Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants) carries an average Medicare payment of $42.52 — 0% below the national benchmark of $42.72. 5 providers across the state submitted claims for this procedure in 2023, performing 327 total services. Individual payments in NJ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in New Jersey is $228.45, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New Jersey sits below the national Medicare average, commercial rates in the state may also run lower than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in New Jersey lands near $108.43, with self-pay cash prices typically around $94.72. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants cost in New Jersey?
The average Medicare payment for Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in New Jersey is $42.52, which is 0% below the national average of $42.72. Providers in NJ typically bill $228.45 for this procedure.
What does Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants cost with insurance in New Jersey?
With commercial insurance in New Jersey, Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants costs an estimated $108.43. Without insurance, the estimated cash price is $94.72. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in New Jersey?
5 providers in New Jersey billed Medicare for Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants in 2023, performing 327 total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants cheaper in New Jersey than the national average?
Yes — Gene Analysis (serpin Peptidase Inhibitor, Clade A, Alpha-1 Antiproteinase, Antitrypsin, Member 1) Common Variants costs 0% below the national average in New Jersey. The state average Medicare payment is $42.52 compared to $42.72 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.